However, IL-7 responsiveness is present in a limited fraction of T-ALL neoplasms, and of these, only a minority show mRNA expression levels of PIM1 that are high enough to be considered a potential therapeutic target44. This evidence concerns the gene IL7 and acute lymphoblastic leukemia.